This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Barr, M. S., & George, T. P. (2014). Biological Psychiatry, 1;76(9):678-80.
This report describes a double-blind, sham-controlled trial that used the Brainsway Deep TMS (Transcranial Magnetic Stimulation) H-Coil for smoking cessation. It was found that, when applied bilaterally on the dorsolateral prefrontal cortex (DLPFC) and insular cortex, the H-coil may decrease short-term biochemically verified smoking and nicotine dependence levels and increase short- and long-term smoking abstinence rates.